Bibliographic Details
| Title: |
Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma. |
| Authors: |
Othman, Tamer, Baird, John H., Pak, Stacy, Mei, Matthew, Herrera, Alex F., Mansour, Joshua, Shouse, Geoffrey, Sahebi, Firoozeh, Spielberger, Ricardo, Cai, Ji‐Lian, Farol, Leonardo, Godfrey, James, Kallam, Avyakta, Phillips, Tycel, Popplewell, Leslie, Siddiqi, Tanya, Forman, Stephen, Budde, Lihua E. |
| Source: |
British Journal of Haematology; Jul2024, Vol. 205 Issue 1, p368-372, 5p |
| Subject Terms: |
SKIN cancer, T cells, INFORMED consent (Medical law) |
| Abstract: |
This article examines the use of axicabtagene ciloleucel (axi-cel), a CAR T-cell therapy, as a second-line treatment for large B-cell lymphoma (LBCL) in a real-world setting. The study analyzes data from patients who received axi-cel at a single center and evaluates various outcomes such as survival rates, response rates, and side effects. The results indicate that axi-cel is effective and well-tolerated, providing valuable insights for its use in clinical practice. However, larger studies with longer follow-up are needed to further validate its efficacy and practicality. [Extracted from the article] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
